Cyclotron and Radiochemistry Specialized Resource

回旋加速器和放射化学专业资源

基本信息

批准号：
8382210
负责人：
NAGICHETTIAR SATYAMURTHY
金额：
$ 7.12万
依托单位：
UNIVERSITY OF CALIFORNIA LOS ANGELES
依托单位国家：
美国
项目类别：
财政年份：
资助国家：
美国
起止时间：
至
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/8382210
关键词：
Acetates Adenovirus Vector Adenoviruses Adopted Adoptive Cell Transfers Affinity Animal Model Animals Applications Grants Automobile Driving Back Basic Science Binding Biological Biological Markers Biology Cancer Biology Cell Proliferation Cell physiology Cells Cellular biology Choline Clinical Collaborations Colorectal Cancer Communities Complement Core Facility Coxibs Cyclotrons Cytosine Deltastab Deoxycytidine Kinase Department of Energy Development Diagnostic Discipline of Nuclear Medicine Earthquakes Enzymes Fatty Acids Fluorides Fostering Funding Gene Expression Genes Glioblastoma Grant Growth Herpesvirus 1 High Pressure Liquid Chromatography Housing Human Image Imaging Device Imaging Techniques Immune Immunocompetent Immunodeficient Mouse Income Individual Inhibitory Concentration 50 Injection of therapeutic agent Institutes Ions Label Laboratories Lesion Lipids Liver Lymphocyte Maintenance Malignant - descriptor Malignant Neoplasms Measures Medical Medical center Medicine Metabolism Modeling Molecular Molecular Biology Molecular Medicine Monitor Mus Nature Nuclear Energy Nuclear Reactors Nucleosides Oncogenic Pathway interactions Patients Peripheral Nerves Plant Roots Play Positron Positron-Emission Tomography Preparation Principal Investigator Procedures Process Production Protons Radioactive Radiochemistry Radioisotopes Radiolabeled Reagent Recording of previous events Reporter Genes Research Research Personnel Research Project Grants Research Support Resource Sharing Resources Retroviral Vector Rewards Role Series Services Signal Transduction Simplexvirus Sirolimus T-Cell Receptor Techniques Therapeutic Thymidine Kinase Time Tracer Transgenic Organisms Tumor Burden United States Virus Work Xenograft Model Xenograft procedure analog base cancer cell chemical property cyclooxygenase 2 gain of function genetic manipulation glucose metabolism imaging probe immune activation in vivo in vivo Cellular and Molecular Imaging Centers instrumentation lipid metabolism meetings molecular imaging mouse model novel nucleoside analog operation oxidation physical property preclinical study programs promoter radiochemical radiotracer repaired research study response sarcoma small molecule soft tissue suicide gene thymidine kinase 1 tool transgene expression tumor tumor growth tumor xenograft vector

项目摘要

Specialized Resource 1 Principal investigator/Program Director (Last, First, Middle): Herschman, Harvey R. D.1. CYCLOTRON AND RADIOCHEMISTRY SPECIALIZED RESOURCE {DIRECTOR, N. SATYAMURTHY. PH.D.) D.1.1. Introduction. The Cyclotron and Radiochemistry facility is a Specialized Resource component of both the UCLA-ICMIC and the UCLA Institute of Molecular Medicine (IMED) program. IMED had it roots in the longstanding Department of Energy-supported effort in positron emission tomography research at UCLA. Our history with the IMED program thus predates the initiation of the NCI ICMIC, extending back for over nearly four decades, when it was associated with the Atomic Energy Commission, and later the Department of Energy. The prime objective of the Cyclotron and Radiochemistry Specialized Resource of the UCLA ICMIC is to support both research and production for all positron-emitting probe needs of UCLA-ICMIC investigators, and to serve other UCLA research projects that complement these research programs. The UCLA Cyclotron and Radiochemistry Specialized Resource began its operation in July 1971. During the 1960s the Division of Biology and Medicine of the US Atomic Energy Commission (AEC, the predecessor of Department of Energy) undertook a program of fostering the installation and operation of compact cyclotrons at several medical centers across the United States. The intent was to stimulate the development of radioactive nuclides as diagnostic tools in medicine by making available a large number of promising radionuclides with desirable physical and chemical properties, but which could not be produced in nuclear reactors. As a consequence, an AEC-sponsored medical cyclotron program was initiated at UCLA and a model CS-22 cyclotron built by the Cyclotron Corporation (Berkeley, CA) capable of accelerating H*, D'', ^He** and ''He^'^ at fixed energies of 22, 12, 31, and 24 MeV, respectively was installed in a specially built vault at UCLA in 1971. A radiochemistry laboratory and a machine shop along with the cyclotron, all housed in a single story building adjacent to the UCLA Medical Center, formed the original cyclotron core laboratory. Due to increasing demand for radioisotopes, in 1990 a new 11 MeV proton RDS-112 negative ion cyclotron (manufactured by CTI, Knoxville TN) in a new building next to the CS-22 cyclotron building was added to the Radiochemistry Specialized Resource. The consequences of the Northridge earthquake of January 1994 mandated a replacement of the CS-22 cyclotron. An 11 MeV proton only RDS-112 negative ion cyclotron (manufactured by CTI Knoxville, TN) replaced the damaged CS-22 accelerator in June 1994. A complete renovation of the cyclotron laboratory took place in 1997, for the first time since the inception of the facility. The new compact, self-shielded RDS-112 cyclotron occupies only one half of the vault that the CS-22 cyclotron previously occupied, allowing the other half to be used for maintenance and repair of cyclotron-related components. The Cyclotron and Radiochemistry Specialized Resource, since its inception in 1971, has an excellent history of supporting the needs of UCLA Nuclear Medicine research. With the CS-22 cyclotron, this Specialized Resource has developed or adopted techniques for the production of more than twenty five different radioisotopes. As a centralized service unit, the Cyclotron and Radiochemistry Specialized Resource in the last nearly forty years has been providing various investigators carrying out Nuclear Medicine related research with positron emitting biomarkers. Until the ICMIC Program began, we supplied positron-emitting probes for studies primarily in large animals and in humans. With the development of microPET instrumentation, along with the influx of cell and molecular biologists who have turned to molecular imaging techniques under the ICMIC auspices, we now find our user base to have increased substantially, and the nature of the research we support to be far more varied. It has been both scientifically profitable and personally rewarding for the Cyclotron and Radiochemistry Specialized Resource staff to expand our interactions with the biological community at UCLA, as a result of the ICMIC extension of molecular imaging techniques throughout our molecular and cell biology community. The Cyclotron and Radiochemistry Specialized Resource is supported in part by income from clinical operations. Additional funds come from ICMIC resources and from individual grants that have Nuclear Medicine support components. Approximately 25% of our radiosynthesis work is for ICMIC programs; the bulk of the remainder of the research syntheses are for related basic sciences studies and for clinical programs. In reality, the clinical income supports and supplements, to some extent, programs that are under the ICMIC aegis.

专业资源 1 首席研究员/项目总监（最后、第一、中间）：Herschman, Harvey R. D.1.回旋加速器和放射化学专业资源{主任，N. SATYAMURTHY。博士） D.1.1。介绍。回旋加速器和放射化学设施是 UCLA-ICMIC 和 UCLA 分子医学研究所 (IMED) 项目的专业资源组成部分。 IMED 的根源在于加州大学洛杉矶分校能源部长期支持的正电子发射断层扫描研究。因此，我们与 IMED 计划的历史早于 NCI ICMIC 的启动，可以追溯到近四十多年前，当时它与原子能委员会以及后来的能源部有联系。 UCLA ICMIC 回旋加速器和放射化学专业资源的主要目标是支持 UCLA-ICMIC 研究人员的所有正电子发射探针需求的研究和生产，并为加州大学洛杉矶分校的其他研究项目提供服务，以补充这些研究项目。加州大学洛杉矶分校回旋加速器和放射化学专业资源于 1971 年 7 月开始运行。在 20 世纪 60 年代，美国原子能委员会（AEC，能源部的前身）生物和医学司开展了一项促进紧凑型回旋加速器和放射化学的安装和操作的计划。美国多个医疗中心的回旋加速器。其目的是通过提供大量具有理想物理和化学性质但无法在核反应堆中生产的有前途的放射性核素来刺激放射性核素作为医学诊断工具的发展。因此，加州大学洛杉矶分校 (UCLA) 启动了一项由 AEC 赞助的医疗回旋加速器计划，并由回旋加速器公司（加利福尼亚州伯克利）建造了型号 CS-22 回旋加速器，能够加速 H*、D''、^He** 和 ''He ^'^ 在固定能量分别为 22、12、31 和 24 MeV，于 1971 年安装在加州大学洛杉矶分校专门建造的金库中。放射化学实验室和机械车间以及回旋加速器都位于加州大学洛杉矶分校医学中心附近的一栋单层建筑中，形成了最初的回旋加速器核心实验室。由于对放射性同位素的需求不断增加，1990 年，CS-22 回旋加速器大楼旁边的一座新大楼中的新 11 MeV 质子 RDS-112 负离子回旋加速器（由田纳西州诺克斯维尔的 CTI 制造）被添加到放射化学专业资源中。 1994 年 1 月北岭地震的后果迫使我们更换 CS-22 回旋加速器。 1994 年 6 月，一台 11 MeV 仅质子 RDS-112 负离子回旋加速器（由田纳西州 CTI 诺克斯维尔制造）取代了损坏的 CS-22 加速器。1997 年对回旋加速器实验室进行了彻底翻新，这是自回旋加速器实验室成立以来的首次该设施。新型紧凑型自屏蔽式RDS-112回旋加速器仅占据CS-22回旋加速器先前占据的拱顶的一半，使另一半可用于回旋加速器相关部件的维护和修理。回旋加速器和放射化学专业资源自 1971 年成立以来，在支持加州大学洛杉矶分校核医学研究的需求方面有着悠久的历史。通过 CS-22 回旋加速器，该专业资源已开发或采用了生产超过 25 种不同放射性同位素的技术。作为一个集中服务单位，回旋加速器和放射化学专业资源在过去近四十年中一直为开展核医学相关研究的各种研究人员提供正电子发射生物标志物。在 ICMIC 计划开始之前，我们主要为大型动物和人类的研究提供正电子发射探针。随着 microPET 仪器的发展，以及细胞和分子生物学家的涌入，他们在 ICMIC 的支持下转向分子成像技术，我们现在发现我们的用户群大幅增加，我们支持的研究的性质也远非如此。更加多样化。由于 ICMIC 将分子成像技术扩展到我们的分子和细胞生物学界，因此对于回旋加速器和放射化学专业资源人员来说，扩大我们与加州大学洛杉矶分校生物学界的互动不仅在科学上有利可图，而且对个人也有回报。回旋加速器和放射化学专业资源部分由临床收入支持运营。额外的资金来自 ICMIC 资源和具有核医学支持部分的个人赠款。我们大约 25% 的放射合成工作是针对 ICMIC 项目；其余的研究综合大部分用于相关的基础科学研究和临床项目。事实上，临床收入在某种程度上支持和补充了 ICMIC 资助的项目。